- Home
- INVE vs MIST Comparison
INVE vs MIST Comparison
Compare INVE & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- MIST
- Stock Information
- Founded
- INVE 1990
- MIST 2003
- Country
- INVE United States
- MIST Canada
- Employees
- INVE N/A
- MIST N/A
- Industry
- INVE Computer peripheral equipment
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- MIST Health Care
- Exchange
- INVE Nasdaq
- MIST Nasdaq
- Market Cap
- INVE 74.2M
- MIST 89.8M
- IPO Year
- INVE 1997
- MIST N/A
- Fundamental
- Price
- INVE $3.50
- MIST $1.60
- Analyst Decision
- INVE Strong Buy
- MIST Strong Buy
- Analyst Count
- INVE 3
- MIST 2
- Target Price
- INVE $6.50
- MIST $7.50
- AVG Volume (30 Days)
- INVE 100.8K
- MIST 1.8M
- Earning Date
- INVE 08-07-2025
- MIST 08-07-2025
- Dividend Yield
- INVE N/A
- MIST N/A
- EPS Growth
- INVE N/A
- MIST N/A
- EPS
- INVE 3.12
- MIST N/A
- Revenue
- INVE $25,239,000.00
- MIST N/A
- Revenue This Year
- INVE N/A
- MIST N/A
- Revenue Next Year
- INVE $9.00
- MIST N/A
- P/E Ratio
- INVE $1.11
- MIST N/A
- Revenue Growth
- INVE N/A
- MIST N/A
- 52 Week Low
- INVE $2.86
- MIST $0.63
- 52 Week High
- INVE $4.35
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- INVE 63.68
- MIST 83.15
- Support Level
- INVE $3.10
- MIST $1.86
- Resistance Level
- INVE $3.61
- MIST $1.97
- Average True Range (ATR)
- INVE 0.14
- MIST 0.14
- MACD
- INVE 0.04
- MIST 0.06
- Stochastic Oscillator
- INVE 79.25
- MIST 100.00
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).